In fact, anti-PD-1/PD-L1 agents are approved for EGFR mutant NSCLC, only after progression on EGFR TKIs, suggesting EGFR TKIs favorably modulate the TME with regard to anti-PD-1/PD-L1 efficacy [32]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.